Javascript must be enabled to continue!
1205 Activity Trackers As A Tool In Sleep Research: Determining Discrepancies In Trackers Vs. PSG
View through CrossRef
Abstract
Introduction
Fitness-based wearables and other emerging sensor technologies have the potential to track sleep across large populations longitudinally in at-home environments. To understand how these devices can inform research studies, limitations of available trackers need to be compared to traditional polysomnography (PSG). Here we assessed discrepancies in sleep staging in activity trackers vs. PSG in subjects with various sleep disorders.
Methods
Twelve subjects (age 41-78, 7f, 5m) wore a Fitbit Charge 3 while undergoing a scheduled sleep study. Six subjects had been previously diagnosed with a sleep disorder (5 OSA, 1 CSA). 4 subjects used CPAP throughout the night, 2 had a split night (CPAP 2nd half of the night), and 6 had a PSG only. Activity tracker staging was compared to 2 RPSGTs staging.
Results
Of the 12 subjects, eight subjects’ sleep was detected in the activity tracker, and compared across sleep stages to the PSG (7 female, 1 male, ages 41-78, AHI 0.3-87, RDI 0.5-94.4, sleep efficiency 74%+/-18, 4 PSG, 1 split, 3 CPAP). The activity tracker matched either tech 52% (+/- 13). The average difference in score tech and activity tracker staging for sleep onset (SO) was 16 +/- 15 minutes and wake after sleep onset was 43.5 +/- 44 minutes. Sensitivity, specificity, and balanced accuracy were found for each sleep stage. Respectively, Wake: 0.45+/-0.27, 0.97+/-0.03, 0.71+/-0.12, REM: 0.41+/-0.30, 0.90+/-0.06, 0.60+/-0.28, Light: 0.71+/-0.09, 0.58+/-0.19, 0.65+/-0.10, Deep: 0.63+/-0.52, 0.88+/-0.05, 0.59+/-0.49.
Conclusion
From this study of 12 subjects seen at a sleep clinic for suspected sleep disorders, activity trackers performed best in wake, REM and deep sleep specificity (>=88%), while they lacked sensitivity to REM and wake (<=45%) stages. The tracker did not detect sleep in 4 subjects who had elevated AHI or low sleep efficiency. Further analysis can identify whether discrepancies between the Fitbit and PSG can be predicted by distinct patterns in sleep staging and/or identify subject exclusion criteria for activity tracking studies.
Support
This project in on-going with the support of Academy Diagnostics Sleep and EEG Center and staff.
Title: 1205 Activity Trackers As A Tool In Sleep Research: Determining Discrepancies In Trackers Vs. PSG
Description:
Abstract
Introduction
Fitness-based wearables and other emerging sensor technologies have the potential to track sleep across large populations longitudinally in at-home environments.
To understand how these devices can inform research studies, limitations of available trackers need to be compared to traditional polysomnography (PSG).
Here we assessed discrepancies in sleep staging in activity trackers vs.
PSG in subjects with various sleep disorders.
Methods
Twelve subjects (age 41-78, 7f, 5m) wore a Fitbit Charge 3 while undergoing a scheduled sleep study.
Six subjects had been previously diagnosed with a sleep disorder (5 OSA, 1 CSA).
4 subjects used CPAP throughout the night, 2 had a split night (CPAP 2nd half of the night), and 6 had a PSG only.
Activity tracker staging was compared to 2 RPSGTs staging.
Results
Of the 12 subjects, eight subjects’ sleep was detected in the activity tracker, and compared across sleep stages to the PSG (7 female, 1 male, ages 41-78, AHI 0.
3-87, RDI 0.
5-94.
4, sleep efficiency 74%+/-18, 4 PSG, 1 split, 3 CPAP).
The activity tracker matched either tech 52% (+/- 13).
The average difference in score tech and activity tracker staging for sleep onset (SO) was 16 +/- 15 minutes and wake after sleep onset was 43.
5 +/- 44 minutes.
Sensitivity, specificity, and balanced accuracy were found for each sleep stage.
Respectively, Wake: 0.
45+/-0.
27, 0.
97+/-0.
03, 0.
71+/-0.
12, REM: 0.
41+/-0.
30, 0.
90+/-0.
06, 0.
60+/-0.
28, Light: 0.
71+/-0.
09, 0.
58+/-0.
19, 0.
65+/-0.
10, Deep: 0.
63+/-0.
52, 0.
88+/-0.
05, 0.
59+/-0.
49.
Conclusion
From this study of 12 subjects seen at a sleep clinic for suspected sleep disorders, activity trackers performed best in wake, REM and deep sleep specificity (>=88%), while they lacked sensitivity to REM and wake (<=45%) stages.
The tracker did not detect sleep in 4 subjects who had elevated AHI or low sleep efficiency.
Further analysis can identify whether discrepancies between the Fitbit and PSG can be predicted by distinct patterns in sleep staging and/or identify subject exclusion criteria for activity tracking studies.
Support
This project in on-going with the support of Academy Diagnostics Sleep and EEG Center and staff.
Related Results
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Abstract 1535: CBA-1205, a novel glycoengineered humanized antibody targeting DLK-1 exhibits potent anti-tumor activity in DLK-1 expressing tumor xenograft models
Abstract 1535: CBA-1205, a novel glycoengineered humanized antibody targeting DLK-1 exhibits potent anti-tumor activity in DLK-1 expressing tumor xenograft models
Abstract
Delta-like 1 homolog (DLK-1) is a type I transmembrane protein with 6 tandem EGF-like motifs in extracellular region. In fetal development, DLK-1 is express...
A Data Driven Approach for Choosing a Wearable Sleep Tracker
A Data Driven Approach for Choosing a Wearable Sleep Tracker
ABSTRACTGoal and AimsTo evaluate the performance of 6 wearable devices across 4 device classes (research-grade EEG-based headband, research-grade actigraphy, high-end consumer trac...
Reciprocal regulation of miR-1205 and E2F1 modulates progression of laryngeal squamous cell carcinoma
Reciprocal regulation of miR-1205 and E2F1 modulates progression of laryngeal squamous cell carcinoma
AbstractThe burgeoning functions of many microRNAs (miRs) have been well study in cancer. However, the level and function of miR-1205 in laryngeal squamous cell cancer remains unkn...
The history of sleep research and sleep medicine in Europe
The history of sleep research and sleep medicine in Europe
SummarySleep became a subject of scientific research in the second half of the 19th century. Since sleep, unlike other physiological functions, cannot be attributed to a specific o...
Median Preoptic Astrocytes: Role in Sleep Regulation and Potential Mediators of Sex Differences
Median Preoptic Astrocytes: Role in Sleep Regulation and Potential Mediators of Sex Differences
One in three Americans suffer from chronic sleep disorders, and women are 40% more likely than men to experience sleep disorders. This disparity emerges at puberty and is strongly ...
A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models
A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models
Abstract: Delta-like 1 homolog (DLK1), a non-canonical Notch ligand, is highly expressed in various malignant tumors, especially in hepatocellular carcinoma (HCC). CBA-1205 is an a...
Evaluation and diagnosis of pediatric obstructive sleep apnea—An update
Evaluation and diagnosis of pediatric obstructive sleep apnea—An update
PurposeFormal overnight polysomnography (PSG) is required to diagnose obstructive sleep apnea (OSA) in children with sleep disordered breathing (SDB). Most clinical guidelines do n...


